



JAN 23 2009

Express Mail Label No. EM 192977509 US Dated: January 23, 2009

Docket No.: AVZ-007CP3RCE
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:
Rima Kaddurah-Daouk *et al.*

Application No.: 09/687,575

Confirmation No.: 9336

Filed: October 13, 2000

Art Unit: 1625

For: COMPOSITIONS CONTAINING A
COMBINATION OF A CREATINE
COMPOUND AND A SECOND AGENT

Examiner: N. Rahmani

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Madam:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have not submitted copies of each cited U.S. patent in accordance with 37 CFR 1.98(a)(2)(ii). Applicants submit herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

Applicants also call to the attention of the Examiner the following commonly owned co-pending applications directed to related subject matter:

Co-Pending Applications			
Serial No.	Filing Date	First Named Inventor	Docket No.
10/718,765	11-21-2003	Rima Kaddurah-Daouk	AVZ-001CPUSCN2RCE

01/26/2009 CCHAU1 00000066 120080 09687575

01 FC:1806 180.00 DA
820512-1

11/899,135	09-04-2007	Rima Kaddurah-Daouk	AVZ-001CPUSCN3
11/342,727	01-30-2006	Rima Kaddurah-Daouk	AVZ-007CP3CN
11/343,116	01-30-2006	Rima Kaddurah-Daouk	AVZ-007CP3CN2
11/473,790	06-23-2006	Rima Kaddurah-Daouk	AVZ-027DV1
11/473,935	06-23-2006	Rima Kaddurah-Daouk	AVZ-027DV2
10/454,752	06-04-2003	Rima Kaddurah-Daouk	AVZ-027RCE
11/803,141	05-11-2007	Belinda Nivaggioli	AVZ-044
12/229,716	08-26-2008	Rima Kaddurah-Daouk	AVZ-027CN
11/803,008	05-11-2007	Belinda Nivaggioli	AVZ-045
12/151,285	05-05-2008	Belinda Nivaggioli	AVZ-048

Applicants understand the Examiner can access additional papers from the prosecution of the cited cases electronically via PALM. However, if the Examiner would like paper copies, he or she is invited to call the undersigned who will supply them.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Supplemental Information Disclosure Statement is filed after the mailing date of a Final Office Action but before payment of the Issue Fee (37 CFR 1.97(d)). Applicants hereby petition that the Supplemental Information Disclosure Statement be considered.

I hereby certify, pursuant to 37 CFR 1.97(e)(2), that no item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, no item of information contained in this Supplemental Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. AVZ-007CP3RCE.

Dated: January 23, 2009

MLR/EJE/mch

Respectfully submitted,

By Meaghan L. Richmond
Meaghan L. Richmond, Ph.D.
Registration No.: 61,402
LAHIVE & COCKFIELD, LLP
One Post Office Square
Boston, Massachusetts 02109-2127
(617) 227-7400
(617) 742-4214 (Fax)
Attorney/Agent For Applicant